Merck gets on the Treg train with Pandion buy
Merck & Co pays $1.9bn for an intriguing but early approach in autoimmune disease.
Biotech flotations offer venture funds an accelerating exit
Start-ups floated faster than usual in 2020, a new analysis finds. For a deeper look at biopharma deal trends, our free report is available to download today.
Bayer’s gene therapy juggling act
Two arm’s-length acquisitions and two licensing deals have given Bayer a cell and gene therapy unit; now to bring it all together.
GW succumbs to a Jazz overture
A focus on rare diseases and regulatory acceptance of cannabis make GW the subject of a $7.2bn buyout.
Horizon pays $3bn to bolster its pipeline
But forecasts of over $3bn in annual peak sales from Viela’s portfolio look steep.
